Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

OTHER

Sponsor class

Conditions

CCND1 Positive
CCND2 Positive
CCND3 Positive
CD20 Positive
Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]